Harvard Bioscience Q2 revenue meet estimates

Harvard Bioscience

11/08/2025 12:09

Overview

Harvard Bioscience Q2 2025 revenue in line with analyst expectations, per LSEG data

Adjusted EPS for Q2 meets analyst estimates, indicating stable performance

Company signs credit amendment, extending refinance deadline to Dec 5, 2025

Outlook

Harvard Bioscience expects Q3 2025 revenue between $19 mln and $21 mln

Company anticipates Q3 2025 gross margin of 56% to 58%

Harvard Bioscience sees improved operations and strong financial discipline

Company aims for revenue growth and margin expansion in 2026

Result Drivers

CASH FLOW IMPROVEMENT - Cash provided by operations improved to $2.8 mln from a negative $0.8 mln in Q2 2024

CREDIT AMENDMENT - New credit amendment signed, extending refinance deadline to December 5, 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Meet
$20.45 mln
$20.40 mln (2 Analysts)
Q2 Adjusted EPS
Meet
-$0.01
-$0.01 (2 Analysts)
Q2 EPS
-$0.05
Q2 Net Income
-$2.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Harvard Bioscience Inc is $3.00, about 82.4% above its August 8 closing price of $0.53

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release: ID:nGNX1ZYVBM

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)